Antibodies specific for peptide corresponding to CD44 exon 6, and use of these antibodies for diagnosis of tumors
AssigneeIsis Innovation Limited
InventorsDavid Tarin, Yasuhiro Matsumura
Life of this patent
Estimating the term…
Abstract
There is marked over-expression of multiple spliced variants of the CD44 gene in tumor compared to counterpart normal tissue. This observation forms the basis of a method of diagnosing neoplasia by analysis of a sample of body tissue or body fluid or waste product. A new exon 6 of 129 bp has been located and sequenced. Antibodies specific to the exon have been prepared and are claimed as new compounds suitable for use in the detection of CD44 proteins and for the in vivo imaging and therapy of tumors.
Claims13
Antibody that specifically binds to the peptide corresponding to CD44 exon 6 having the amino acid sequence shown in FIG. 7 (SEQ ID NO:1), its allele variations and phosphorylation and glycosylation products.
Monoclonal antibody which specifically binds to the peptide corresponding to CD44 exon 6 having the amino acid sequence shown in FIG. 7 (SEQ ID NO:1) obtainable by the hybridoma cell lines MAK<CD44>M-1.1.12, MAK<CD44>M-2.42.3 or MAK<CD44>M-4.3.16, Accession Numbers DSM ACC2156, DSM ACC2157 or DSM ACC2158, respectively.
Immunoassay for the detection of a CD44 protein contained in the peptide corresponding to CD44 exon 6 wherein an antibody that specifically binds to the peptide CD44 exon 6 having the amino acid sequence shown in FIG. 7 (SEQ ID NO:1), or its allele variations is used.
Dependencies are inferred from the claim text.